1077 related articles for article (PubMed ID: 1762085)
21. Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728.
Mousa SA; Forsythe MS; Diemer M; Bozarth JM; Reilly TM
Coron Artery Dis; 1994 Nov; 5(11):919-27. PubMed ID: 7719524
[TBL] [Abstract][Full Text] [Related]
22. The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction.
Gram J
Dan Med Bull; 1990 Jun; 37(3):210-34. PubMed ID: 2192835
[TBL] [Abstract][Full Text] [Related]
23. Ticlopidine facilitates the deaggregation of human platelets aggregated by thrombin.
Cattaneo M; Akkawat B; Kinlough-Rathbone RL; Packham MA; Cimminiello C; Mannucci PM
Thromb Haemost; 1994 Jan; 71(1):91-4. PubMed ID: 8165651
[TBL] [Abstract][Full Text] [Related]
24. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
25. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity.
Kumar R; Béguin S; Hemker HC
Thromb Haemost; 1995 Sep; 74(3):962-8. PubMed ID: 8571330
[TBL] [Abstract][Full Text] [Related]
26. Platelets interact with fibrin only after activation.
Hantgan RR; Taylor RG; Lewis JC
Blood; 1985 Jun; 65(6):1299-311. PubMed ID: 3888311
[TBL] [Abstract][Full Text] [Related]
27. Effects of ionic and nonionic contrast media on clot structure, platelet function and thrombolysis mediated by tissue plasminogen activator in plasma clots.
Carr ME; Carr SL; Merten SR
Haemostasis; 1995; 25(4):172-81. PubMed ID: 7557656
[TBL] [Abstract][Full Text] [Related]
28. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
29. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
[TBL] [Abstract][Full Text] [Related]
30. Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation.
Martínez C; Rivera J; Loyau S; Corral J; González-Conejero R; Lozano ML; Vicente V; Anglés-Cano E
Thromb Haemost; 2001 Apr; 85(4):686-93. PubMed ID: 11341506
[TBL] [Abstract][Full Text] [Related]
31. The effect of flow on lysis of plasma clots in a plasma environment.
Sakharov DV; Rijken DC
Thromb Haemost; 2000 Mar; 83(3):469-74. PubMed ID: 10744155
[TBL] [Abstract][Full Text] [Related]
32. Tridegin, a novel peptidic inhibitor of factor XIIIa from the leech, Haementeria ghilianii, enhances fibrinolysis in vitro.
Seale L; Finney S; Sawyer RT; Wallis RB
Thromb Haemost; 1997 May; 77(5):959-63. PubMed ID: 9184410
[TBL] [Abstract][Full Text] [Related]
33. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
Trusen B; Ries M; Zenker M; Rauh M; Beinder E; Keuper H; Harms D
Semin Thromb Hemost; 1998; 24(6):599-604. PubMed ID: 10066156
[TBL] [Abstract][Full Text] [Related]
34. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
Nielsen VG
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
[TBL] [Abstract][Full Text] [Related]
35. Effects of streptokinase, urokinase, and recombinant tissue plasminogen activator on platelet aggregability and stability of platelet aggregates.
Terres W; Umnus S; Mathey DG; Bleifeld W
Cardiovasc Res; 1990 Jun; 24(6):471-7. PubMed ID: 2167173
[TBL] [Abstract][Full Text] [Related]
36. Halysin, an antiplatelet Arg-Gly-Asp-containing snake venom peptide, as fibrinogen receptor antagonist.
Huang TF; Liu CZ; Ouyang CH; Teng CM
Biochem Pharmacol; 1991 Aug; 42(6):1209-19. PubMed ID: 1888330
[TBL] [Abstract][Full Text] [Related]
37. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
Onundarson PT; Francis CW; Marder VJ
J Lab Clin Med; 1992 Jul; 120(1):120-8. PubMed ID: 1613318
[TBL] [Abstract][Full Text] [Related]
38. Aggregation of washed platelets by plasminogen and plasminogen activators is mediated by plasmin and is inhibited by a synthetic peptide disulfide.
Puri RN; Hu CJ; Matsueda R; Umeyama H; Colman RW
Thromb Res; 1992 Mar; 65(4-5):533-47. PubMed ID: 1535463
[TBL] [Abstract][Full Text] [Related]
39. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration.
Andrew M; Brooker L; Leaker M; Paes B; Weitz J
Thromb Haemost; 1992 Sep; 68(3):325-30. PubMed ID: 1440499
[TBL] [Abstract][Full Text] [Related]
40. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets.
Gartner TK; Bennett JS
J Biol Chem; 1985 Oct; 260(22):11891-4. PubMed ID: 2995350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]